Orexigen Therapeutics and Takeda partnership to commercialise Contrave in ... - Trading Markets (press release)
Posted by admin / Under Prescription Drug Marketing Act Genetic Engineering News | Orexigen Therapeutics and Takeda partnership to commercialise Contrave in ... Trading Markets (press release) The company had submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Contrave on 31 March 2010 and the Prescription Drug ... Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave ... Orexigen(R) Therapeutics and Takeda Enter Into Partnership to Commercialize ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
Allergan Resolves United States Government Investigation of Past Sales and ... - MarketWatch (press release)
Posted by admin / Under Prescription Drug Marketing Act Kansas City Star | Allergan Resolves United States Government Investigation of Past Sales and ... MarketWatch (press release) A prescription drug is deemed misbranded when its labeling does not contain adequate directions for its "intended uses," and, under the Government's view, ... Allergan Settles Investigation Regarding Botox Labeling Allergan Pays $600 Million To Settle Botox Marketing Charges ALLERGAN AGREES TO PLEAD GUILTY AND PAY $600 MILLION TO RESOLVE ALLEGATIONS OF ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
OREX and Takeda Partner Up, Stock Update On CRWE and BRCD From PennyToBuck.com - Penny Stock Live (blog)
Posted by admin / Under Prescription Drug Marketing ActOREX and Takeda Partner Up, Stock Update On CRWE and BRCD From PennyToBuck.com Penny Stock Live (blog) OREX submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Contrave on March 31, 2010 and the Prescription Drug User Fee ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
Glaxo, Valeant May Wait 3 More Months for US FDA to Review Epilepsy Drug - Bloomberg
Posted by admin / Under Prescription Drug Marketing Act ABC2 News | Glaxo, Valeant May Wait 3 More Months for US FDA to Review Epilepsy Drug Bloomberg The Food and Drug Administration pushed back the targeted date under the Prescription Drug User Fee Act to review ezogabine to Nov. 30 from Aug. ... GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine US FDA puts off decision on Meda's ezogabine |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
User fees for generic drugs - what are the issues? - Lexology (registration)
Posted by admin / Under Prescription Drug Marketing ActUser fees for generic drugs - what are the issues? Lexology (registration) How, if at all, should a generic drug user fee program differ from FDA's existing user fee programs, including the Prescription Drug User Fee Act (“PDUFA”), ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
Questions loom over drug given to sleepless vets - The Associated Press
Posted by admin / Under Prescription Drug Marketing ActQuestions loom over drug given to sleepless vets The Associated Press Seroquel has been the VA's second-biggest prescription drug expenditure since 2007, behind the blood-thinner Plavix. The agency spent $125.4 million last ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
WEISS v. AstraZENECA PHARMACEUTICALS - Leagle.com
Posted by admin / Under Prescription Drug Marketing ActWEISS v. AstraZENECA PHARMACEUTICALS Leagle.com As part of its regulation of prescription drug advertising, FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) reviews promotional ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
SmallCapReview.com: Stocks To Watch - CCGI, CRME, MRK, OREX - Trading Markets (press release)
Posted by admin / Under Prescription Drug Marketing ActSmallCapReview.com: Stocks To Watch - CCGI, CRME, MRK, OREX Trading Markets (press release) Orexigen submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Contrave on March 31, 2010 and the Prescription Drug User ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
Fighting an epidemic: New tools to inhibit counterfeiting - Packaging Digest
Posted by admin / Under Prescription Drug Marketing Act Packaging Digest | Fighting an epidemic: New tools to inhibit counterfeiting Packaging Digest Congress passed the Prescription Drug Marketing Act (PDMA) in 1987, creating a chain of custody tracking requirement for distributors of prescription drugs ... |
Published on Thursday 2nd of September 2010 07:26:18 PM
Read more...
